The pharmaceutical collaboration page explicitly covers target discovery, biomarker research, clinical trial assay (CTA) development, and companion diagnostics. Distinct from diagnostic product sales; included as diversified, with group financials.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY PRC Accounting Standards / consolidated
3,705,385,018.37
-616,655,148.27 Net income attributable to shareholders of the listed company
Consolidated group totals include diagnostic, research and other products/services; they are not CRO or central laboratory segment revenue.
Parent-attributable net income is a loss. The reported 31.69% year-over-year change indicates a narrowing loss, not positive earnings growth.
2026Q3 (YTD) · Reporting notes
Consolidated group totals include diagnostic, research and other products/services; they are not CRO or central laboratory segment revenue.
Q3 2026 comparatives were retrospectively restated for a business combination under common control. Revenue and its year-over-year change use the restated comparatives. Net income growth of 335.29% reflects a change from a negative prior-period base to profit.
Original 2025 annual report amounts and the restated comparative base in the Q3 2026 report cover different scopes and should not be mixed.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The website explicitly describes target, biomarker, CTA, and CDx collaborations with domestic and overseas pharmaceutical companies since 2010. This evidence is on the listed BGI Genomics website.
SZSE:300676; the 2025 annual report and latest 2026 report were read from original consolidated statements.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
